David Butters, DO
Family Medicine · Layton, UTNPI 1932272598
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $156,661 of the $189,239 with a category attached, or 82.8%. 60 manufacturers reported payments, led by AbbVie at 54.7% of the total. Reporting peaked in 2023 at $62,272 and has fallen 59.8% since, to $25,063 in 2025. Among family medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 950 payments — averaging $199.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$103K
- Axsome Therapeutics, Inc.$22K
- AstraZeneca$16K
- Idorsia Pharmaceuticals US Inc$13K
- Sunovion Pharmaceuticals Inc.$13K
- Otsuka America Pharmaceutical, Inc.$12K
- plus $9K from 54 others
What the payments were for
- Consulting fees$11,7756%
- Speaking & faculty fees$156,66183%
- Travel & lodging$7,2064%
- Food & beverage$13,4457%
- Education$1530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$99,753
- Auvelity$21,460
- AIRSUPRA$14,873
- QUVIVIQ$12,938
- LATUDA$12,579
- REXULTI$11,354
- TRINTELLIX$1,265
- NURTEC ODT$1,200
- CAPLYTA$245
- FARXIGA$227
- ELIQUIS$124
- ABILIFY MAINTENA$122
- Saxenda$118
How this compares
$189,239 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $164,181 |
| VraylarCariprazine Hcl | 53 | $76,272 |
| FarxigaDapagliflozin Propanediol | 61 | $62,683 |
| EliquisApixaban | 78 | $56,561 |
| MyrbetriqMirabegron | 89 | $50,760 |
| TrulicityDulaglutide | 33 | $43,270 |
| XareltoRivaroxaban | 36 | $34,672 |
| TrintellixVortioxetine Hydrobromide | 39 | $34,345 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $29,196 |
| MounjaroTirzepatide | 14 | $20,632 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $19,992 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $18,429 |
| LinzessLinaclotide | 22 | $14,978 |
| JardianceEmpagliflozin | 20 | $13,312 |
| UbrelvyUbrogepant | 12 | $12,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $328 | $171,994160 claims |
| AbbVieVraylar, Linzess, Ubrelvy | $103,464 | $103,54387 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $16,065 | $91,216111 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $510 | $63,90247 claims |
| PfizerEliquis | $400 | $56,56178 claims |
| Astellas Pharma US IncMyrbetriq | $427 | $50,76089 claims |
| Johnson & JohnsonXarelto | $264 | $34,67236 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,491 | $34,34539 claims |
| GSKTrelegy Ellipta | $246 | $29,19634 claims |
| Boehringer IngelheimJardiance | $466 | $13,31220 claims |
| MerckBelsomra | $61 | $8,48119 claims |
| Sanofi-aventis U.S. LLCLantus | $168 | $4,10014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 928 family medicine providers in Utah.
Other family medicine in Layton
- Courtney NelsonLayton$190K
- Layne BarkerLayton$13K
- Johnnie CookLayton$9K
- Kevin GardnerLayton$9K
- Jared MorrisLayton$8K
- Jeffery DegrauwLayton$8K
- Rachel HobbsLayton$8K
- Marc AndersonLayton$8K
- Michael SchaellingLayton$8K
- Michael CobbleSandy$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.